Alligator Bioscience AB (OSTO:ATORX)

kr 0.546 0.009 (1.68%) Market Cap: 413.89 Mil Enterprise Value: 376.05 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 22/100

Q3 2024 Alligator Bioscience AB Earnings Call Transcript
Oct 24, 2024

kr0.853 (-26.97%)

Earnings
Q2 2024 Alligator Bioscience AB Earnings Call Transcript
Jul 11, 2024

kr1.2 (+3.10%)

Earnings
Q4 2023 Alligator Bioscience AB Earnings Call Transcript
Feb 09, 2024

kr0.945 (-11.68%)

Earnings
Q2 2023 Alligator Bioscience AB Earnings Call Transcript
Jul 13, 2023

kr0.425 (-1.39%)

Earnings
Q1 2023 Alligator Bioscience AB Earnings Call Transcript
Apr 25, 2023

kr0.72 (+8.00%)

Earnings
Q4 2022 Alligator Bioscience AB Earnings Call Transcript
Feb 10, 2023

kr1.01 (-13.72%)

Earnings
Q3 2022 Alligator Bioscience AB Earnings Call Transcript
Oct 20, 2022

kr0.860606 (-3.92%)

Earnings
Alligator Bioscience AB at Redeye Growth Day (Virtual) Transcript
Jun 02, 2022
Q1 2022 Alligator Bioscience AB Earnings Call Transcript
Apr 27, 2022

kr1.13 (+1.63%)

Earnings
Q4 2021 Alligator Bioscience AB Earnings Call Transcript
Feb 11, 2022

kr1.49 (+1.65%)

Earnings
Q3 2021 Alligator Bioscience AB Earnings Call Transcript
Oct 22, 2021

kr1.57 (+4.81%)

Earnings
Q2 2021 Alligator Bioscience AB Earnings Call Transcript
Jul 13, 2021

kr3.25 (-1.68%)

Earnings
Q4 2020 Alligator Bioscience AB Earnings Call Transcript
Feb 26, 2021

kr3.65 (-0.45%)

Earnings
Alligator Bioscience AB at Biostock Life Science Summit (Virtual) Transcript
Nov 18, 2020
Q3 2020 Alligator Bioscience AB Earnings Call Transcript
Oct 22, 2020

kr4.95 (+3.10%)

Earnings
Alligator Bioscience AB R&D Market Update Transcript
Aug 27, 2020
Alligator Bioscience AB at AACR Virtual Annual Meeting Transcript
Apr 27, 2020
Q4 2019 Alligator Bioscience AB Earnings Call Transcript
Feb 12, 2020

kr4.69 (-1.79%)

Earnings

Alligator Bioscience AB at Redeye Growth Day (Virtual) Transcript

Jun 02, 2022 / NTS GMT

Release Date Price: kr0.88606 (+0.41%)

Transcript

SÃ;ren Bregenholt

Alligator Bioscience AB - CEO

¸ -

Hi. I'm SÃ¸ren Bregenholt. I'm the CEO of Alligator Bioscience. It's a pleasure being with you today. So Alligator Bioscience is a clinical-stage biotech company with a deep and broad pipeline in best-in-class, both monoclonal and bispecific, antibodies and a range of novel monoclonal bispecific antibody technologies. We are listed on NASDAQ in Stockholm and headquartered in Lund in the southern part of Sweden.

Our lead asset, mitazalimab, is being developed in first-line pancreatic cancer in combination with chemotherapy. And we are currently conducting a Phase II study here. In addition, we have a differentiated pipeline with several near- to mid-term value drivers. And our leading antibody technologies are well positioned to sustain longer-term value generation for Alligator. In addition, we have several pipeline assets that are mature for out-licensing.

We built a strong team with a proven track record for global biotech and pharma, making us well suited to deliver both in product development, on operational execution of

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.